相似文献
1
Update on the management of non-muscle invasive bladder cancer.
Can Urol Assoc J. 2010 Feb;4(1):56-64. doi: 10.5489/cuaj.777.
2
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Eur Urol. 2020 Jan;77(1):101-109. doi: 10.1016/j.eururo.2019.09.029. Epub 2019 Nov 5.
3
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
4
Non-Muscle Invasive Bladder Cancer: A Review of the Current Trend in Africa.
World J Oncol. 2019 Jun;10(3):123-131. doi: 10.14740/wjon1210. Epub 2019 Jun 29.
5
Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.
Eur Urol Focus. 2019 Jul;5(4):681-688. doi: 10.1016/j.euf.2017.09.002. Epub 2017 Oct 23.
6
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
Eur Urol. 2017 Nov;72(5):801-813. doi: 10.1016/j.eururo.2017.04.015. Epub 2017 Apr 28.
7
Review on gender differences in non-muscle invasive bladder cancer.
Transl Androl Urol. 2019 Feb;8(1):12-20. doi: 10.21037/tau.2018.11.06.
8
Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.
Mini Rev Med Chem. 2020;20(12):1133-1152. doi: 10.2174/1389557516666160512151202.
9
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
10
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Epub 2013 Jun 12.
引用本文的文献
1
PAQR4: A Critical Senescence-Related Gene Influencing Immune Evasion and Metastasis in Bladder Urothelial Carcinoma.
Hum Mutat. 2025 Sep 12;2025:2227219. doi: 10.1155/humu/2227219. eCollection 2025.
2
Hydrogel technologies in andrology: advances in research and prospective applications.
Front Pharmacol. 2025 Jul 28;16:1635007. doi: 10.3389/fphar.2025.1635007. eCollection 2025.
3
Tolerability and efficacy of induction Bacillus Calmette-Guérin for non-muscle invasive bladder cancer.
Bladder (San Franc). 2025 Apr 11;12(2):e21200031. doi: 10.14440/bladder.2024.0051. eCollection 2025.
4
From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer.
Cancers (Basel). 2025 Mar 28;17(7):1135. doi: 10.3390/cancers17071135.
5
Recent Advances and Emerging Innovations in Transurethral Resection of Bladder Tumor (TURBT) for Non-Muscle Invasive Bladder Cancer: A Comprehensive Review of Current Literature.
Res Rep Urol. 2025 Mar 14;17:69-85. doi: 10.2147/RRU.S386026. eCollection 2025.
6
Effect of hypoxia-induced mIL15 expression on expansion and memory progenitor stem-like TILs .
Front Immunol. 2024 Nov 22;15:1450245. doi: 10.3389/fimmu.2024.1450245. eCollection 2024.
7
Metastasis development in non-muscle-invasive bladder cancer.
Nat Rev Urol. 2024 Nov 20. doi: 10.1038/s41585-024-00963-y.
8
ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol.
BMJ Open. 2024 Jun 10;14(6):e076763. doi: 10.1136/bmjopen-2023-076763.
9
BCG induced lower urinary tract symptoms during treatment for NMIBC-Mechanisms and management strategies.
Front Neurosci. 2024 Jan 8;17:1327053. doi: 10.3389/fnins.2023.1327053. eCollection 2023.
10
MRI/RNA-Seq-Based Radiogenomics and Artificial Intelligence for More Accurate Staging of Muscle-Invasive Bladder Cancer.
Int J Mol Sci. 2023 Dec 20;25(1):88. doi: 10.3390/ijms25010088.
本文引用的文献
1
Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.
Int J Urol. 2008 Apr;15(4):309-13. doi: 10.1111/j.1442-2042.2008.02012.x.
2
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
J Urol. 2007 Dec;178(6):2314-30. doi: 10.1016/j.juro.2007.09.003.
3
Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results.
Eur Urol. 2008 Jan;53(1):45-52. doi: 10.1016/j.eururo.2007.08.015. Epub 2007 Aug 20.
4
Natural history, recurrence, and progression in superficial bladder cancer.
ScientificWorldJournal. 2006 Mar 27;6:2617-25. doi: 10.1100/tsw.2006.404.
5
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
J Urol. 2007 Jul;178(1):62-7. doi: 10.1016/j.juro.2007.03.034. Epub 2007 May 11.
6
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Eur Urol. 2007 Nov;52(5):1398-406. doi: 10.1016/j.eururo.2007.04.062. Epub 2007 Apr 27.
7
Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
Urology. 2007 Apr;69(4):675-9. doi: 10.1016/j.urology.2006.12.023.
8
Cancer statistics, 2007.
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.
9
The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
J Urol. 2006 Sep;176(3):935-9. doi: 10.1016/j.juro.2006.04.104.
10
Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.
Urol Oncol. 2006 Jul-Aug;24(4):344-8. doi: 10.1016/j.urolonc.2005.11.026.
Zotero 插件